Your browser doesn't support javascript.
loading
Estudio de biodisponibilidad comparativa de dos formulaciones de risperidona existentes en el mercado chileno / Comparative bioavailability study of two formulations of risperidone available in the Chilean market
Gaete, L. E; Solís, J; Venegas, P; Carrillo, M. J; Schatloff, O; Saavedra, I.
  • Gaete, L. E; Universidad de Chile. ICBM. Programa de Farmacología Molecular y Clínica. CL
  • Solís, J; s.af
  • Venegas, P; s.af
  • Carrillo, M. J; s.af
  • Schatloff, O; s.af
  • Saavedra, I; s.af
Rev. méd. Chile ; 131(5): 527-534, mayo 2003.
Article Dans Espagnol | LILACS | ID: lil-356107
ABSTRACT

BACKGROUND:

Bioavailability of a particular drug can vary according to the formulation used. Therefore, studies of comparative bioavailability of different formulations of a same drug are worthwhile.

AIM:

To compare the bioavailability of two risperidone formulations available in the Chilean market. MATERIAL AND

METHODS:

The bioavailability of a local risperidone formulation (Spiron) was compared with the original formulation of the drug (Risperdal) in 12 healthy volunteers, aged 19 +/- 1 years. A single dose of 3 mg was given orally, using a randomized double blind protocol in two periods. Fifteen blood samples were obtained at regular intervals, until 24 h after drug administration. Risperidone plasma levels were measured by high pressure liquid chromatography. pharmacokinetic parameters were calculated using a computer program that is independent of compartmental analysis.

RESULTS:

The area under the curve of plasma concentration versus time, from 0 to infinite (ABC0-infinity) and from 0 to 24 h (ABC0-24), early exposure (ABC from 0 to maximal time) and maximal plasma concentrations were significantly lower for Spiron. Half life time and time to achieve the maximal concentration were similar for the two formulations.

CONCLUSIONS:

According to bioequivalence tests suggested by the Food and Drug Administration (FDA) of the United States (90 per cent confidence interval for the difference of long transformed mean pharmacokinetic parameters), the formulations Risperdal and Spiron, cannot be considered interchangeable.
Sujets)
Texte intégral: Disponible Indice: LILAS (Amériques) Sujet Principal: Neuroleptiques / Rispéridone Type d'étude: Essai clinique contrôlé / Étude pronostique Limites du sujet: Adolescent / Adulte / Humains / Mâle Pays comme sujet: Amérique du Sud / Chili langue: Espagnol Texte intégral: Rev. méd. Chile Thème du journal: Médicament Année: 2003 Type: Article Pays d'affiliation: Chili Institution/Pays d'affiliation: Universidad de Chile/CL

Documents relatifs à ce sujet

MEDLINE

...
LILACS

LIS

Texte intégral: Disponible Indice: LILAS (Amériques) Sujet Principal: Neuroleptiques / Rispéridone Type d'étude: Essai clinique contrôlé / Étude pronostique Limites du sujet: Adolescent / Adulte / Humains / Mâle Pays comme sujet: Amérique du Sud / Chili langue: Espagnol Texte intégral: Rev. méd. Chile Thème du journal: Médicament Année: 2003 Type: Article Pays d'affiliation: Chili Institution/Pays d'affiliation: Universidad de Chile/CL